Ranibizumab degeneration

Ranibizumab Anti-FAB fragment of VEGF Macular degeneration... 

Ferrara N, Damico L, Shams N, et al (2006) Developmemt of Ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 859-870... 

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. 

Neovascular macular degeneration Ranibizumab (labeled), bevacizumab (unlabeled) Fair... 

Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. The ANCHOR Smdy Group. N Engl J Med 2006 355 1432. 

Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007 143 566. 

Heier JS,AntoszykAN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration. A phase 1/11 multicenter, controlled, multidose smdy. Ophthalmology 2006 113 633. 

Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006 113 623. 

Macular Degeneration) compared monthly ranibizumab (0.3 Or 0.5 mg) to PDT in patients with predominantly classic CNVM. At one year, approximately 95% of ranibizumab-treated patients had lost less than 15 letters, compared to 64% of those in the PDT group. Vision improved by 15 or more letters in 37.5% (0.3-mg group) and 40.3% (0.5-mg group) of ranibizumab-treated patients. 

Ranibizumab (Lucentisj 2006 Humanized 48 3-9 days from vitreous humor intravitreal injection (low serum concentrations) Vascular endothelial growth factor Wet-type macular degeneration... 

Schmucker C, Ehlken C, Hansen LL, Antes G, Agostini HT, Lelgemann M. Intravi-treal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration a systematic review. Curr Opin Ophthalmol 2010 21 218-26. 

The intraocular injection of active substances that are active in the eye leads to a bioavaUability of 100 %. However, this route of administration is a serious burden to the patient and formulation related safety aspects are of paramount importance since ehmination from the site of injection is generally slow. However, this route may be the only way to get an active substance to the site of action, or to get it in a sufficiently high concentration at the site of action (e.g., an antibiotic). Larger molecules such as monoclonal antibodies (e.g., bevacizumab or ranibizumab used against macular degeneration) are administered in this way to the eye. A further advantage of the intraocular route is that the large molecules are cleared slowly from the intraocular fluids and effects may last for days (or even weeks). 

Ranibizumab Humanized IgGlK Fab E. coli VEGF -A Angiogenesis inhibitor Macular degeneration Lucentis ... 

Comparative studies Adverse reactions have been studied in 32 patients with exudative age-related macular degeneration who received standard fluence photodynamic therapy with verteporfin at baseline and months 3, 6, and 9 and ranibizumab 0.5 mg at baseline and months 1, 2, and 3 [5 ]. The main adverse reactions outcome measure was severe loss of vision (a loss of best-corrected visual acuity of at least 30 letters). There was no severe loss of vision due to ocular inflammation or uveitis. One patient had moderate loss of vision (of at least 15 letters). Three patients had mild/moderate uveitis. There were two serious ocular adverse events (a retinal pigment epithelial tear and a moderate reduction in best-corrected visual acuity). There were no systemic adverse events. 

Sensory systems Eyes In 138 patients with subfoveal choroidal neovascular age-related macular degeneration who received ranibizumab 0.5 mg the observed adverse events were vitreous hemorrhage (n = 1), extrafoveal tears in the retinal pigment epithelium (n = 13 9%), conjunctival hemorrhages n = 33 24%), small floaters... 

Retinal pigment epithelium tears can complicate exudative age-related macular degeneration or its treatment. An 81-year-old woman with retinal angiomatous proliferation and pigment epithelial detachment had a retinal pigment epithelial tear 10 days after an intravitreal injection of ranibizumab [12 ]. 

In 11 patients with exudative age-related macular degeneration who received verfe-profin -I- pdt and ranibizumab, optical coherence tomography showed that subret-inal and intraretinal leakage increased with verteporfin but resolved after 2 weeks [21 ]. Non-perfusion of small/medium choroidal vessels occurred, and although reperfusion began after 1 month it was not restored completely. 

Boyer DS, Heier JS, Brown DM, Francom SF, lanchulev T, Rubio RG. A phase inb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration. Ophthalmology 2009 116 1731-9. 

Brown DM, Michels M, Kaiser PK, Heier JS, Sy IP, lanchulev T. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration two-year results of the ANCHOR Study. Ophthalmology 2009 116 57-65. 

Rothenbuehler SP, Waeber D, Brinkmann CK, Wolf S, Wolf-Schnurrbusch UEK. Effects of ranibizumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol 2009 147 831-7. 

---